MX2024010440A - Tratamiento del cancer con un conjugado anticuerpo-farmaco anti-ror2 condicionalmente activo ror2. - Google Patents

Tratamiento del cancer con un conjugado anticuerpo-farmaco anti-ror2 condicionalmente activo ror2.

Info

Publication number
MX2024010440A
MX2024010440A MX2024010440A MX2024010440A MX2024010440A MX 2024010440 A MX2024010440 A MX 2024010440A MX 2024010440 A MX2024010440 A MX 2024010440A MX 2024010440 A MX2024010440 A MX 2024010440A MX 2024010440 A MX2024010440 A MX 2024010440A
Authority
MX
Mexico
Prior art keywords
drug conjugate
cancer treatment
polypeptide
chain variable
variable region
Prior art date
Application number
MX2024010440A
Other languages
English (en)
Spanish (es)
Inventor
Eric Sievers
Philippe Martin
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of MX2024010440A publication Critical patent/MX2024010440A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024010440A 2022-02-25 2023-02-24 Tratamiento del cancer con un conjugado anticuerpo-farmaco anti-ror2 condicionalmente activo ror2. MX2024010440A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263313943P 2022-02-25 2022-02-25
PCT/US2023/063226 WO2023164618A1 (en) 2022-02-25 2023-02-24 Cancer treatment with a conditionally active anti-ror2 antibody-drug conjugate

Publications (1)

Publication Number Publication Date
MX2024010440A true MX2024010440A (es) 2024-09-05

Family

ID=87766744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010440A MX2024010440A (es) 2022-02-25 2023-02-24 Tratamiento del cancer con un conjugado anticuerpo-farmaco anti-ror2 condicionalmente activo ror2.

Country Status (10)

Country Link
US (1) US20250161472A1 (https=)
EP (1) EP4482870A1 (https=)
JP (1) JP2025508819A (https=)
KR (1) KR20240153580A (https=)
CN (1) CN119095877A (https=)
AU (1) AU2023226070A1 (https=)
CA (1) CA3244077A1 (https=)
MX (1) MX2024010440A (https=)
TW (1) TW202342537A (https=)
WO (1) WO2023164618A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322234A1 (en) * 2012-01-03 2014-10-30 The Board Of Trustees Of The Leland Stanford Junior University Analysis and Targeting of ROR2 in Cancer
US11673957B2 (en) * 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
WO2017127702A1 (en) * 2016-01-20 2017-07-27 The Scripps Research Institute Ror2 antibody compositions and related methods
CN116751298A (zh) * 2016-05-13 2023-09-15 生物蛋白有限公司 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
BR112022009611A2 (pt) * 2019-11-18 2022-08-09 Univ California Anticorpos anti-ror-2 e métodos de uso

Also Published As

Publication number Publication date
JP2025508819A (ja) 2025-04-10
WO2023164618A1 (en) 2023-08-31
KR20240153580A (ko) 2024-10-23
EP4482870A1 (en) 2025-01-01
CA3244077A1 (en) 2023-08-31
CN119095877A (zh) 2024-12-06
TW202342537A (zh) 2023-11-01
AU2023226070A1 (en) 2024-09-05
US20250161472A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
MX2022016192A (es) Anticuerpos anti-nectina-4 condicionalmente activos.
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
PE20240913A1 (es) Anticuerpos anti-il-2r agonistas y metodos de uso
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
BR112023002150A2 (pt) Anticorpos direcionando egfr e uso dos mesmos
AR077998A1 (es) Proteinas terapeuticas de union a dll4
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
AR114544A1 (es) Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
MX2018013306A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
PE20080100A1 (es) ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5ß1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA
PE20050712A1 (es) Anticuerpos rg1
BR112022006817A2 (pt) Anticorpos direcionados a flt3 e uso dos mesmos
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.
MX2022013882A (es) Anticuerpos dirigidos contra el miembro a de la familia de dominios de lectina tipo c 12 (clec12a) y uso de los mismos.
MX2024003913A (es) Anticuerpos dirigidos al receptor del factor activador de celulas b (baff-r) y uso de los mismos.
CO2025002301A2 (es) Anticuerpos anti-ccr8 y métodos de uso
MX2023004089A (es) Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12.
MX2024010440A (es) Tratamiento del cancer con un conjugado anticuerpo-farmaco anti-ror2 condicionalmente activo ror2.
MX2024001834A (es) Metodos para tratar el cancer de vejiga no muscular invasivo (nmibc) con conjugados de anticuerpos y farmacos (adc) que se unen a las proteinas 191p4d12.